Followers | 507 |
Posts | 10138 |
Boards Moderated | 0 |
Alias Born | 04/28/2014 |
Tuesday, April 14, 2015 11:33:53 AM
macd crossup
Sage Therapeutics, Inc.
215 First Street
Cambridge, MA 02142
United States
Phone: 617-299-8380
Fax: 617-299-8379
Website: http://www.sagerx.com
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes novel medicines to treat life-threatening and rare central nervous system disorders. The company's lead product candidate includes SAGE-547, an intravenous (IV) agent that is in Phase I/II clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE). Its pipeline also includes second-generation molecules, such as SAGE-217, an oral therapy for orphan genetic epilepsies; and SAGE-689, an adjunctive intravenous second-line therapy for the treatment of refractory status epilepticus. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is based in Cambridge, Massachusetts.
Recent SAGE News
- Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress • Business Wire • 04/25/2024 10:30:00 AM
- Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease • Business Wire • 04/17/2024 10:30:00 AM
- Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024 • Business Wire • 04/11/2024 10:30:00 AM
- Sage Therapeutics to Present at Upcoming March Investor Conferences • Business Wire • 02/28/2024 11:30:00 AM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 02/21/2024 09:35:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 10:02:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 10:02:15 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:09:44 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/14/2024 12:49:08 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/14/2024 12:20:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 11:45:53 AM
- Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress • Business Wire • 02/14/2024 11:30:00 AM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 01/31/2024 10:25:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 09:50:55 PM
- Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024 • Business Wire • 01/31/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/24/2024 09:10:55 PM
- Form SC TO-I - Tender offer statement by Issuer • Edgar (US Regulatory) • 01/23/2024 01:13:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 11:45:04 AM
- Sage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare Conference • Business Wire • 01/08/2024 11:32:00 AM
- Sage Therapeutics Announces Changes to Board of Directors • Business Wire • 01/08/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:07:58 PM
- Sage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 • Business Wire • 01/02/2024 11:30:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/19/2023 01:32:56 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/19/2023 01:30:28 PM
- ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S. • GlobeNewswire Inc. • 12/14/2023 11:30:00 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM